Wangxia LV
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC (NCT06379399) | Wangxia LV | 2024-04-01 |
Track Wangxia LV automatically
Every clearance here is in the API, with alerts when new ones post.